*/
Drug and alcohol misuse remains a frequent factor in family law proceedings, directly impacting assessments of parenting capacity, safeguarding, and contact arrangements.
Standard drug testing panels are designed to detect the most commonly misused substances – such as opiates, cocaine and cannabis. However, an increasing number of family law cases involve non-standard drugs: substances not routinely included in standard panels, yet capable of causing dependency, behavioural instability, and impaired parenting.
Non-standard drugs include anything not typically found on a standard testing panel, and include substances such as anabolic steroids, prescription medications (e.g. pregabalin, gabapentin, oxycodone) and hallucinogens (e.g. LSD, PCP, mescaline).
These substances may be incorrectly perceived by users as undetectable or ‘safe’ and are often obtained via online pharmacies or illicit markets. However, their misuse can result in detrimental psychological, behavioural and cognitive effects, with serious implications for child welfare and court assessments.
Steroid misuse is rarely addressed in family law contexts, yet its impact can be significant. These drugs are increasingly used by individuals – often men – seeking enhanced physical appearance or performance.
Chronic or high-dose use is associated with aggression, mood instability, and impaired judgement.
Where there are concerns about erratic or aggressive behaviour, especially in contact disputes, targeted testing for steroids should be considered.
Misuse of prescription medication has risen sharply, with many drugs used recreationally for their sedative, euphoric or pain-relieving effects, often in combination with other substances. Examples include:
As these drugs are not included in standard panels, misuse may go undetected without specific instruction. Even individuals with valid prescriptions may be at risk of dependency, potentially affecting their ability to care for children safely.
Hallucinogens such as LSD, PCP and mescaline are gaining popularity, particularly among individuals engaged in polysubstance misuse (using multiple drugs together). These substances can induce paranoia, hallucinations, and dissociation, significantly impairing emotional regulation and risk perception. Effects can also persist long after use, raising serious safeguarding concerns. Although less commonly abused than mainstream substances, targeted testing is essential where hallucinogen use is suspected or unexplained behavioural issues are present.
AlphaBiolabs continually monitors emerging trends in drug misuse and validates new substances in the laboratory, providing legal professionals with bespoke testing options. Our standard drug panel includes the top nine court-ordered drugs: methamphetamine, opiates, cocaine, cannabis, amphetamine, benzodiazepines, ketamine, methadone and tramadol. Where additional substances are suspected, our non-standard panel can be tailored to include prescription medications (e.g. antidepressants, gabapentinoids), hallucinogens, anabolic steroids and many, many more.
Marie Law is Director of Toxicology at AlphaBiolabs. A highly-skilled and respected scientist with over 15 years’ experience in the field of forensics, Marie joined AlphaBiolabs in 2022 and oversees the company’s growing toxicology team. As Director of Toxicology, Marie’s day-to-day responsibilities include maintaining the highest quality testing standards for toxicology and further enhancing AlphaBiolabs’ drug and alcohol testing services for the legal sector, members of the public, and the workplace sector.
Drug and alcohol misuse remains a frequent factor in family law proceedings, directly impacting assessments of parenting capacity, safeguarding, and contact arrangements.
Standard drug testing panels are designed to detect the most commonly misused substances – such as opiates, cocaine and cannabis. However, an increasing number of family law cases involve non-standard drugs: substances not routinely included in standard panels, yet capable of causing dependency, behavioural instability, and impaired parenting.
Non-standard drugs include anything not typically found on a standard testing panel, and include substances such as anabolic steroids, prescription medications (e.g. pregabalin, gabapentin, oxycodone) and hallucinogens (e.g. LSD, PCP, mescaline).
These substances may be incorrectly perceived by users as undetectable or ‘safe’ and are often obtained via online pharmacies or illicit markets. However, their misuse can result in detrimental psychological, behavioural and cognitive effects, with serious implications for child welfare and court assessments.
Steroid misuse is rarely addressed in family law contexts, yet its impact can be significant. These drugs are increasingly used by individuals – often men – seeking enhanced physical appearance or performance.
Chronic or high-dose use is associated with aggression, mood instability, and impaired judgement.
Where there are concerns about erratic or aggressive behaviour, especially in contact disputes, targeted testing for steroids should be considered.
Misuse of prescription medication has risen sharply, with many drugs used recreationally for their sedative, euphoric or pain-relieving effects, often in combination with other substances. Examples include:
As these drugs are not included in standard panels, misuse may go undetected without specific instruction. Even individuals with valid prescriptions may be at risk of dependency, potentially affecting their ability to care for children safely.
Hallucinogens such as LSD, PCP and mescaline are gaining popularity, particularly among individuals engaged in polysubstance misuse (using multiple drugs together). These substances can induce paranoia, hallucinations, and dissociation, significantly impairing emotional regulation and risk perception. Effects can also persist long after use, raising serious safeguarding concerns. Although less commonly abused than mainstream substances, targeted testing is essential where hallucinogen use is suspected or unexplained behavioural issues are present.
AlphaBiolabs continually monitors emerging trends in drug misuse and validates new substances in the laboratory, providing legal professionals with bespoke testing options. Our standard drug panel includes the top nine court-ordered drugs: methamphetamine, opiates, cocaine, cannabis, amphetamine, benzodiazepines, ketamine, methadone and tramadol. Where additional substances are suspected, our non-standard panel can be tailored to include prescription medications (e.g. antidepressants, gabapentinoids), hallucinogens, anabolic steroids and many, many more.
Chair of the Bar reflects on 2025
Q&A with criminal barrister Nick Murphy, who moved to New Park Court Chambers on the North Eastern Circuit in search of a better work-life balance
Revolt Cycling in Holborn, London’s first sustainable fitness studio, invites barristers to join the revolution – turning pedal power into clean energy
Rachel Davenport, Co-founder and Director at AlphaBiolabs, reflects on how the company’s Giving Back ethos continues to make a difference to communities across the UK
By Marie Law, Director of Toxicology at AlphaBiolabs
AlphaBiolabs has made a £500 donation to Sean’s Place, a men’s mental health charity based in Sefton, as part of its ongoing Giving Back initiative
Professor Dominic Regan and Seán Jones KC present their best buys for this holiday season
Little has changed since Burns v Burns . Cohabiting couples deserve better than to be left on the blasted heath with the existing witch’s brew for another four decades, argues Christopher Stirling
Six months of court observation at the Old Bailey: APPEAL’s Dr Nisha Waller and Tehreem Sultan report their findings on prosecution practices under joint enterprise
Despite its prevalence, autism spectrum disorder remains poorly understood in the criminal justice system. Does Alex Henry’s joint enterprise conviction expose the need to audit prisons? asks Dr Felicity Gerry KC
With automation now deeply embedded in the Department for Work Pensions, Alexander McColl and Alexa Thompson review what we know, what we don’t and avenues for legal challenge
